Citius Pharmaceuticals, Inc. Warrant
CTXRW
CTXRW was delisted on the 8th of August, 2022.
1 hedge funds and large institutions have $1K invested in Citius Pharmaceuticals, Inc. Warrant in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more capital invested
Capital invested by funds: $1K → $1K ($0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1K | +$4 | +26 | +0.4% |
|
CTXRW Hedge Fund Activity: Q4 2019 in Review
1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals, Inc. Warrant (CTXRW) for Q4 2019, worth a combined $1K — unchanged from a quarter earlier.
Fund positioning in CTXRW was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $4.
- 1 institutional investor held Citius Pharmaceuticals, Inc. Warrant (CTXRW) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1K of Citius Pharmaceuticals, Inc. Warrant stock for Q4 2019, unchanged quarter-over-quarter.
- 0 funds opened new Citius Pharmaceuticals, Inc. Warrant positions in Q4 2019 and 0 closed out.
- The largest Citius Pharmaceuticals, Inc. Warrant buyer in Q4 2019 was UBS Group, an estimated $4 added.
Based on aggregated 13F filings for Q4 2019.